The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Erasca reported updated Phase 1 data for its cancer candidate ERAS-0015 and priced an upsized $550 million public stock offering. Following this, the U.S. FDA granted Fast Track designation to pelareorep for treating advanced anal canal carcinoma. Additionally, Monopar Therapeutics initiated a rolling New Drug Application submission for ALXN1840 to treat Wilson disease.